Azusa Komori

628 total citations
28 papers, 259 citations indexed

About

Azusa Komori is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Surgery. According to data from OpenAlex, Azusa Komori has authored 28 papers receiving a total of 259 indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Oncology, 16 papers in Pulmonary and Respiratory Medicine and 11 papers in Surgery. Recurrent topics in Azusa Komori's work include Gastric Cancer Management and Outcomes (14 papers), Colorectal Cancer Treatments and Studies (10 papers) and Metastasis and carcinoma case studies (4 papers). Azusa Komori is often cited by papers focused on Gastric Cancer Management and Outcomes (14 papers), Colorectal Cancer Treatments and Studies (10 papers) and Metastasis and carcinoma case studies (4 papers). Azusa Komori collaborates with scholars based in Japan. Azusa Komori's co-authors include Shigenori Kadowaki, Kei Muro, Takashi Ura, Yukiya Narita, Hiroya Taniguchi, Masashi Ando, Yasushi Yatabe, Chihiro Kondoh, Seiichiro Mitani and Masahiro Tajika and has published in prestigious journals such as Journal of Clinical Oncology, Annals of Oncology and Medicine.

In The Last Decade

Azusa Komori

26 papers receiving 258 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Azusa Komori Japan	10	149	129	104	27	22	28	259
Takatsugu Ogata Japan	8	156 1.0×	107 0.8×	57 0.5×	20 0.7×	19 0.9×	45	229
Vikas Ostwal India	9	158 1.1×	58 0.4×	81 0.8×	24 0.9×	20 0.9×	63	273
Abdullah Sakin Türkiye	10	178 1.2×	97 0.8×	77 0.7×	42 1.6×	29 1.3×	66	294
Takaaki Furukawa Japan	12	269 1.8×	137 1.1×	134 1.3×	34 1.3×	15 0.7×	60	357
Yoshiki Horie Japan	7	180 1.2×	161 1.2×	103 1.0×	24 0.9×	18 0.8×	30	266
Ryo Sadachi Japan	8	136 0.9×	103 0.8×	125 1.2×	25 0.9×	34 1.5×	26	233
Takafumi Mie Japan	12	302 2.0×	163 1.3×	150 1.4×	32 1.2×	15 0.7×	68	394
Klisthenis Tsamakidis Greece	8	173 1.2×	61 0.5×	216 2.1×	12 0.4×	12 0.5×	17	297
Takeshi Suto Japan	8	179 1.2×	78 0.6×	99 1.0×	15 0.6×	39 1.8×	34	268
Giuseppina Arcangeli Italy	7	227 1.5×	101 0.8×	69 0.7×	35 1.3×	58 2.6×	11	336

Countries citing papers authored by Azusa Komori

Since Specialization

Citations

This map shows the geographic impact of Azusa Komori's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Azusa Komori with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Azusa Komori more than expected).

Fields of papers citing papers by Azusa Komori

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Azusa Komori. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Azusa Komori. The network helps show where Azusa Komori may publish in the future.

Co-authorship network of co-authors of Azusa Komori

This figure shows the co-authorship network connecting the top 25 collaborators of Azusa Komori. A scholar is included among the top collaborators of Azusa Komori based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Azusa Komori. Azusa Komori is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Kodama, Hiroko, Yukiya Narita, Michio Nakamura, et al.. (2025). A multicenter, prospective, observational study of nivolumab readministration for advanced gastric cancer (NIVO RETURNS). Future Oncology. 21(14). 1753–1759.

Mitani, Seiichiro, Yosuke Kito, Kentaro Kawakami, et al.. (2023). Real-World Treatment Sequencing in Vulnerable Patients with Metastatic Colorectal Cancer: A Multicenter Retrospective Study. Targeted Oncology. 18(5). 707–715. 2 indexed citations

Komori, Azusa, Satoshi Otsu, Mototsugu Shimokawa, et al.. (2023). Scoring model with serum albumin and CA19-9 for metastatic pancreatic cancer in second-line treatment: results from the NAPOLEON study. International Journal of Clinical Oncology. 28(8). 1073–1081. 1 indexed citations

Shirakawa, Tsuyoshi, Mototsugu Shimokawa, Taiga Otsuka, et al.. (2023). MO61-6 Efficacy of third-line chemotherapy after liposomal irinotecan and fluorouracil with folinic acid for pancreatic cancer. Annals of Oncology. 34. S1435–S1435.

Nishikawa, Kazuo, Shuichi Hironaka, Takashi Inagaki, et al.. (2022). A multicentre retrospective study comparing site-specific treatment with empiric treatment for unfavourable subset of cancer of unknown primary site. Japanese Journal of Clinical Oncology. 52(12). 1416–1422. 2 indexed citations

Shibuki, Taro, Toshihiko Mizuta, Mototsugu Shimokawa, et al.. (2022). Prognostic nomogram for patients with unresectable pancreatic cancer treated with gemcitabine plus nab–paclitaxel or FOLFIRINOX: A post–hoc analysis of a multicenter retrospective study in Japan (NAPOLEON study). BMC Cancer. 22(1). 19–19. 7 indexed citations

Hironaka, Shuichi, Azusa Komori, Ryunosuke Machida, et al.. (2020). The association of primary tumor site with acute adverse event and efficacy of definitive chemoradiotherapy for cStage II/III esophageal cancer: an exploratory analysis of JCOG0909. Esophagus. 17(4). 417–424. 8 indexed citations

Mitani, Seiichiro, Shigenori Kadowaki, Azusa Komori, et al.. (2020). A Phase II Study of Modified FOLFOX6 for Advanced Gastric Cancer Refractory to Standard Therapies. Advances in Therapy. 37(6). 2853–2864. 5 indexed citations

Kondoh, Chihiro, Shigenori Kadowaki, Azusa Komori, et al.. (2018). Salvage chemotherapy with the combination of oxaliplatin, leucovorin, and 5-fluorouracil in advanced gastric cancer refractory or intolerant to fluoropyrimidines, platinum, taxanes, and irinotecan. Gastric Cancer. 21(6). 1050–1057. 15 indexed citations

10.

Masuishi, Toshiki, Hiroya Taniguchi, Tetsuya Eto, et al.. (2018). Morphologic Response and Tumor Shrinkage as Early Predictive Markers in Unresectable Colorectal Liver Metastases. Anticancer Research. 38(11). 6501–6506. 4 indexed citations

11.

Hasegawa, Hiroko, Hiroya Taniguchi, Seiichiro Mitani, et al.. (2017). Efficacy of Second-Line Bevacizumab-Containing Chemotherapy for Patients with Metastatic Colorectal Cancer following First-Line Treatment with an Anti-Epidermal Growth Factor Receptor Antibody. Oncology. 92(4). 205–212. 6 indexed citations

12.

Masuishi, Toshiki, Shigenori Kadowaki, Azusa Komori, et al.. (2017). FOLFOX as First-line Therapy for Gastric Cancer with Severe Peritoneal Metastasis. Anticancer Research. 37(12). 7037–7042. 26 indexed citations

13.

Taniguchi, Hiroya, Azusa Komori, Yukiya Narita, et al.. (2016). A short interval between bevacizumab and anti-epithelial growth factor receptor therapy interferes with efficacy of subsequent anti-EGFR therapy for refractory colorectal cancer. Japanese Journal of Clinical Oncology. 46(3). 228–233. 14 indexed citations

14.

Nomura, Motoo, Isao Oze, Takeshi Kodaira, et al.. (2016). Comparison between surgery and definitive chemoradiotherapy for patients with resectable esophageal squamous cell carcinoma: a propensity score analysis. International Journal of Clinical Oncology. 21(5). 890–898. 18 indexed citations

15.

Taniguchi, Hiroya, Azusa Komori, Yukiya Narita, et al.. (2015). A single-arm phase II trial of combined chemotherapy with S-1, oral leucovorin, and bevacizumab in heavily pre-treated patients with metastatic colorectal cancer. BMC Cancer. 15(1). 601–601. 10 indexed citations

16.

Nomura, Motoo, Isao Oze, Tetsuya Abe, et al.. (2015). Impact of docetaxel in addition to cisplatin and fluorouracil as neoadjuvant treatment for resectable stage III or T3 esophageal cancer: a propensity score-matched analysis. Cancer Chemotherapy and Pharmacology. 76(2). 357–363. 13 indexed citations

17.

Kadowaki, Shigenori, Azusa Komori, Daisuke Takahari, et al.. (2015). Clinical Characteristics Associated with Long-term Survival in Metastatic Gastric Cancer after Systemic Chemotherapy. Asian Pacific Journal of Cancer Prevention. 16(13). 5433–5438. 7 indexed citations

18.

Narita, Yukiya, Hiroya Taniguchi, Koji Komori, et al.. (2014). Differences in attitude toward adjuvant chemotherapy between colorectal cancer survivors and the medical staff of Japanese hospitals. International Journal of Clinical Oncology. 20(4). 755–760. 2 indexed citations

19.

Kadowaki, Shigenori, Azusa Komori, Yukiya Narita, et al.. (2013). Long-term outcomes and prognostic factors of patients with advanced gastric cancer treated with S-1 plus cisplatin combination chemotherapy as a first-line treatment. International Journal of Clinical Oncology. 19(4). 656–661. 8 indexed citations

20.

Kadowaki, Shigenori, Yasushi Yatabe, Hitoshi Hirakawa, et al.. (2013). Complete Response to Trastuzumab-Based Chemotherapy in a Patient with Human Epidermal Growth Factor Receptor-2-Positive Metastatic Salivary Duct Carcinoma ex Pleomorphic Adenoma. Case Reports in Oncology. 6(3). 450–455. 34 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact